Newer agents for the management of overactive bladder

American Family Physician

Volumn 74, Issue 12, 2006, Pages 2061-2068

  Epstein, Benjamin J ^a,b   Gums, John G ^a   Molina, Emerson ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG ELIMINATION; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TABLET FORMULATION; URINE INCONTINENCE; XEROSTOMIA;

HUMANS; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; PELVIC FLOOR; URINARY BLADDER, OVERACTIVE;

EID: 33845537059     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Enablex (darifenacin) [Prescribing information]. Stein, Switzerland: Novartis, 2005.
2. Ditropan (oxybutynin chloride) [Prescribing information]. Raritan, N.J.: Ortho McNeill Pharmaceutical, 2003.
3. Ditropan XL (oxybutynin chloride) [Package insert]. Mountain View, Calif.: ALZA, 2003.
4. Oxytrol (oxybutynin transdermal system) [Package insert]. Corona, Calif.: Watson Pharma, 2003.
5. Vesicare (solifenacin succinate) [Package insert]. Paramus, N.J.: Yamanouchi Pharma America, 2004.
6. Detrol (tolterodine tartrate) [Package insert]. New York, N.Y.: Pfizer, 2005.
7. Detrol LA (tolterodine tartrate) [Package insert]. New York, N.Y.: Pfizer, 2004.
8. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
9. Sanctura (trospium chloride) [Prescribing information]. Hanover, N.J.: Odyssey Pharmaceuticals, 2004.
10. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001.
11. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5 pt 1):1919-24.
12. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, for the Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171(6 pt 1):2311-5.
13. 3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005;23:248-52.
14. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al., for the YM-905 Study Group. Randomized double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10.
15. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
16. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, Hofner K, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9.
17. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs. drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000.
18. Bo K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. BMJ 1999;318:487-93.
19. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. JAMA 2004;291:986-95.
20. Andersson KE, Appell R, Awad S, Chapple C, Drutz H, Finkbeiner A, et al. Pharmacological treatment of urinary incontinence. In Abrams P, Cardozo L, Khoury S, Wein AJ. Incontinence. 2nd ed. Plymouth, UK: Plymbridge Distributors, 2002:479-513.
21. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
22. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004;64:1643-56.
23. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95.
24. Abrams P, Malone-Lee J, Jacquetin B, Wyndaele JJ, Tammela T, Jonas U, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551-60.
25. Diokno A, Sand P, Labasky R, Sieber P, Antoci J, Leach G, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002;34:43-9.
26. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;(3):CD005429.
27. Diokno AC, Apell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
28. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988-93.
29. Van Kerrebroeck PHEV, for the Tolterodine study group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OAB). Int Urogynecol J 2001;12(suppl 3):549.
30. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20:470-5.
31. Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002;3:CD003781.
32. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004;5:423-6.
33. Osca-Garcia JM, Martinez-Aguilo E, Conejero-Sugranes J, Jimenez-Cruz JF. A comparison of trospium chloride and oxybutynin in the treatment of hyperactive bladder: a randomized double-blind study. Urod A 1997;10:40-4.
34. Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995;75:452-6.
35. Haab F, Halasaka M, Klaver M, for the Solifenacin Study Group. Favorable efficacy and tolerability with long-term solifenacin treatment support high patient persistence. Poster 272. Paper presented at: Annual Meeting of the International Continence Society; August 25-27, 2004; Paris, France.
36. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study [Published correction appears in BJU Int 2004;93:1135]. BJU Int 2004;93:71-7.
37. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 2005;173:1214-8.